TOPAZ
Research type
Research Study
Full title
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)
IRAS ID
156654
Contact name
Alasdair Coles
Contact email
Sponsor organisation
Genzyme Corporation
Eudract number
2013-003884-71
Research summary
This is a long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409). The study will provide long term safety, efficacy and Quality of Life data on the patients who completed at least 48 weeks of the CAMMS03409 study, as well as on additional as-needed alemtuzumab re-treatment. In addition, the study will provide information about the safety profile of patients who received other commercial Disease Modifying Treatments following alemtuzumab treatment.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
14/EE/1113
Date of REC Opinion
3 Oct 2014
REC opinion
Further Information Favourable Opinion